{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-25-000004","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.863253+00:00","generated_at":"2026-05-28T03:42:36.617060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)","bullets":["Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.","Full-year 2024 product revenue ~$160M, up ~449% compared to 2023, driven by ZORYVE demand.","Cash and marketable securities ~$229M as of Dec 31, 2024; total liquidity ~$329M after $100M debt repayment and re-draw option.","Gross-to-net similar to prior quarter; robust unit growth across portfolio.","Company to report complete Q4/FY2024 results and host conference call on Feb 25, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-25-000004","json":"https://secwatch.observer/filing/0001787306-25-000004.json","markdown":"https://secwatch.observer/filing/0001787306-25-000004.md","text":"https://secwatch.observer/filing/0001787306-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/0001787306-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/arqt-20250112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T03:42:36.617060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}